Figure 3.

Use of CMR and 18F-FDG PET for the diagnosis and monitoring of cardiac sarcoidosis. Patients with normal CMR are unlikely to have significant cardiac involvement and may be monitored clinically. Select patients with high clinical suspicion of cardiac sarcoidosis and normal CMR might be considered for ¹⁸F-FDG PET. CMR may be preferable to ¹⁸F-FDG PET as a first line test to minimize ionizing radiation, although local institutional expertise may influence test choice. Patients with inflammation by ¹⁸F-FDG PET should be considered for anti-inflammatory therapy and repeat ¹⁸F-FDG PET imaging in 3–6 months to evaluate response to therapy. EF, ejection fraction; CMR, cardiac magnetic resonance; ¹⁸F-FDG PET, ¹⁸F-fluorodeoxyglucose positron emission tomography; ICD, implantable cardiac defibrillator.